Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 22: 1806-1811, 1976;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szasz, G
Right arrow Articles by Bernt, E
Right arrow Search for Related Content
PubMed
Right arrow Articles by Szasz, G
Right arrow Articles by Bernt, E

Clinical Chemistry, Vol 22, 1806-1811, Copyright © 1976 by American Association for Clinical Chemistry

Creatine kinase in serum: 2. Interference of adenylate kinase with the assay

G Szasz, W Gerhardt, W Gruber and E Bernt

Interference of adenylate kinase with Oliver's method [Biochem. J. 61, 116 (1955)] for creatine kinase is usually suppressed by including an adenylate kinase inhibitor, AMP. We studied the kinetics and compared the inhibition capacities of AMP and diadenosine pentaphosphate. Both are competitive inhibitors, AMP being markedly weaker, with a Ki of about 300 mumol/liter for adenylate kinase from erythrocyte, muscle, and liver. AMP also weakly inhibitis creatine kinase. Diadenosine pentaphosphate inhibits erythrocyte and muscle adenylate kinase strongly (Ki about 0.03 mumol/liter), the liver isoenzyme less strongly (Ki about 3 mumol/liter), and has no effect on creatine kinase up to 100 mumol/liter. All three adenylate kinases may be present in a patinet's serum, causing sample blanks to be high in a creatine kinase assay that lacks inhibitors. In acute hepatic damage, liver adenylate kinase activity in serum can be grossly increased. Use of sufficient diadenosine pentaphosphate alone for complete inhibition is relatively expensive. Consequently, we recommend a combination of both inhibitors. Diadenosine pentaphosphate, 10 mumol, combined with 5 mmol of AMP per liter inhibits adenylate kinase from erythrocytes and muscle by 97% and from liver by 95%.


The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
R. Rej
They Use Enzymes for Everything!
Clin. Chem., June 1, 1998; 44(6): 1149 - 1153.
[Full Text] [PDF]


Home page
ANGIOLOGYHome page
L. Szlavy, I. Repa, I. Lengye, and L. Lamboy
Effects of Intravenous Streptokinase and CLS 2210 (Calcium Dobesilate) on the Biochemical Markers of Early Acute Myocardial Infarction: A Historic Comparison with Both Studies
Angiology, September 1, 1992; 43(9): 741 - 747.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by the American Association for Clinical Chemistry.